Zydus Lifesciences Ltd

15/02/2026

We are back with the Hyderabad Edition of Zydus Pinkathon and to kick-off, we have Dr. Senthil Rajappa on stage talking about Easiest Exam and the importance self-breast examination.

12/02/2026

We are proud to share that Zydus’ Flu Vaccine campaign has won Gold for the Best Use of Radio at the Indian Marketing Awards, one of the most respected recognitions in India’s marketing and communications ecosystem.

09/02/2026

Our group has been recognised for Excellence in Pharma Program Management (Team) at the Project Management Awards 2026 – Pharma, presented during the 9th Annual Pharma Project & Portfolio Management 2026, held at Renaissance Goa.

In our first-ever participation, we were evaluated on stringent criteria and selected by an experienced jury for demonstrating measurable impact. The awards featured 79 nominations across 6 categories, with participation from 20+ leading pharma organisations.

This recognition reinforces our enterprise-level programme management approach, focused on outcome-driven governance, cross-functional integration, and disciplined ex*****on. This enables stronger portfolio throughput, ex*****on reliability, and cost leadership.

06/02/2026

Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease.

29/01/2026

Zydus Lifesciences has launched Tishtha™, the world's first biosimilar version of the cancer immunotherapy drug nivolumab in India. This is a significant milestone for oncology treatment access in the country.

26/01/2026

26/01/2026

Wish you all Happy republic day.

26/01/2026

Happy republic day.

24/01/2026

Our Managing Director, Dr. Sharvil Patel took the stage to recognize the outstanding contributions of our teams, starting with the Best Brand and Best Plant awards for this year.

22/01/2026

Zydus launches the world’s first biosimilar of Nivolumab, ‘Tishtha™’, in India to treat multiple cancers.

13/01/2026

Sentynl Therapeutics Inc., a Zydus Group company, has received FDA approval for ZYCUBO® (copper histidinate). This approval establishes ZYCUBO® as the first and only therapy approved in the United States for the treatment of Menkes disease.

01/01/2026

Health is wealth